Reconsider FDA policy on screening human tissue donors for sepsis.

requested the Food and Drug Administration (FDA) to reconsider its policy on screening human tissue donors for sepsis

Dingell asked FDA to revisit donor screening standards for sepsis.

Latest News | Congresswoman Debbie Dingell
primary · press_release · model gpt-5.4-mini

Congress.gov lists Debbie Dingell as a Democratic House member from Michigan, in Congress from 2015 to present, representing MI-12 from 2015-2023 and MI-6 from 2023-present.

Establishes the relevant federal service window. FDA action in 2025 occurred during Dingell's later House service, not her initial 2015-2016 term.

unresolved later_term

Congress.gov Member Profile: Representative Debbie Dingell
secondary · model gpt-5.5 · confidence 96%

FDA's 2007 HCT/P donor-eligibility guidance treated sepsis as a relevant communicable disease concern and described donor screening based on medical history, clinical evidence, and physical evidence.

Shows the preexisting FDA policy on screening human tissue donors for sepsis that the promise sought to have reconsidered.

unresolved unknown

FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products
secondary · model gpt-5.5 · confidence 94%

FDA's tissue-guidance index lists a May 2025 draft guidance titled Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by HCT/Ps, alongside the 2007 donor-eligibility guidance.

Official FDA index confirms FDA opened a new sepsis-specific HCT/P guidance process in 2025, after Dingell entered Congress.

partial later_term

FDA Tissue Guidances
secondary · model gpt-5.5 · confidence 93%

FDA says the May 2025 sepsis HCT/P guidance is draft and not for implementation; it updates 2007 sepsis information and would update donor-screening recommendations when finalized.

This is evidence of reconsideration, but because the current posted guidance is draft and nonbinding, it supports partial rather than fully final delivery as of 2026-07-03.

partial later_term

FDA: Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by HCT/Ps
secondary · model gpt-5.5 · confidence 90%

The May 2025 FDA draft says a final sepsis HCT/P guidance was published in January 2025, later revised on timing, then withdrawn and reissued as a draft after comments.

FDA not only reconsidered the topic but changed course after feedback. The withdrawal and reissuance indicate active reconsideration, while the lack of final status keeps the outcome partial.

partial later_term

FDA Draft Guidance: Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by HCT/Ps
secondary · model gpt-5.5 · confidence 91%